TY - JOUR T1 - Inexpensive, versatile and open-source methods for SARS-CoV-2 detection JF - medRxiv DO - 10.1101/2020.09.16.20193466 SP - 2020.09.16.20193466 AU - Thomas G.W. Graham AU - Claire Dugast-Darzacq AU - Gina M. Dailey AU - Xammy H. Nguyenla AU - Erik Van Dis AU - Meagan N. Esbin AU - Abrar Abidi AU - Sarah A. Stanley AU - Xavier Darzacq AU - Robert Tjian Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20193466.abstract N2 - Re-opening of communities in the midst of the ongoing COVID-19 pandemic has ignited a second wave of infections in many places around the world. Mitigating the risk of reopening will require widespread SARS-CoV-2 testing, which would be greatly facilitated by simple, rapid, and inexpensive testing methods. To this end, we evaluated several protocols for RNA extraction and RT-qPCR that are simpler and less expensive than prevailing methods. First, we show that isopropanol precipitation provides an effective means of RNA extraction from nasopharyngeal (NP) swab samples. Second, we evaluate direct addition of NP swab samples to RT-qPCR reactions without an RNA extraction step. We describe a simple, inexpensive swab collection solution suitable for direct addition, which we validate using contrived swab samples. Third, we describe an open-source master mix for RT-qPCR and show that it permits detection of viral RNA in NP swab samples. Lastly, we show that an end-point fluorescence measurement provides an accurate diagnostic readout without requiring a qPCR thermocycler. Adoption of these simple, inexpensive methods has the potential to significantly reduce the time and expense of COVID-19 testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge funding from the Howard Hughes Medical Institute (Grant CC34430 to R.T.) This work was largely funded by the discretionary funds of Xavier Darzacq and Robert Tjian. T.G. is supported by a postdoctoral fellowship from the Jane Coffin Childs Memorial Fund for Medical Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UC Berkeley Office for Protection of Human Subjects concluded that our project does not meet the threshold definition of human subjects research set forth in Federal Regulations at 45 CFR 46.102(f). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data from this manuscript are available upon request. ER -